Bayer supporting GARFIELD, an atrial fibrillation registry
This article was originally published in Scrip
A research grant from Bayer Schering Pharma is supporting GARFIELD (the global anticoagulant registry in the field), the first-ever global atrial fibrillation registry. It will follow, for six years, 50,000 patients from 32 countries who are newly diagnosed with atrial fibrillation. GARFIELD is the first prospective registry in the condition; clinical sites will be selected at random to avoid selection bias, and patients included whether or not they receive anticoagulant therapy. The study is being conducted by the Thrombosis Research Institute, which is affiliated with Queen Mary University of London.
You may also be interested in...
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.